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O Edema macular diabético é a principal causa de perda de visão moderada entre a 
população diabética. Fotocoagulação a laser e controlo intensivo da glicémia e da pressão 
arterial têm sido a abordagem terapêutica padrão por mais de 20 anos. No entanto, na 
maioria dos casos de edema macular diabético difuso e grave, o controlo da doença não é 
satisfatório. A crescente compreensão da patofisiologia multifactorial do edema macular 
incentivou a investigação de novas terapias na última década. Tanto os corticosteroides e 
como os inibidores do fator de crescimento endotelial vascular (bevacizumab, 
ranibizumab, pegaptanib e aflibercept) foram amplamente estudados e mostraram 
melhorias anatómicas e funcionais satisfatórias, com perfis de segurança aceitáveis. 
Infelizmente, alguns dos principais efeitos adversos dos corticosteroides e a necessidade de 
múltiplas injeções intravítreas permanecem grandes preocupações. Sistemas intravitreos de 
libertação sustentada de drogas foram desenvolvidos para reduzir estes e outros eventos 
adversos relacionados com as drogas e as injeções. A vitrectomia mostra ser valiosa apenas 
em alguns casos selecionados, geralmente associados a anomalias da interface vítreo-
retiniana. Novos sistemas de aplicação de laser têm sido desenvolvidos para reduzir os 
eventos adversos relacionados com o laser. Algumas novas drogas experimentais estão 
também em investigação. A maioria dos estudos publicados têm interesse limitado devido 
ao pequeno número de participantes e ao curto período de acompanhamento. Além disso, 
os seus resultados são de difícil comparação, devido a desenhos de estudo e características 
diferentes. O número crescente de publicações e terapias em desenvolvimento revela o 
crescente interesse neste assunto. Uma abordagem multimodalidade pode tornar-se o 
padrão de tratamento para uma doença multifatorial como o edema macular diabético. 
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Diabetic macular edema is the main cause of moderate vision loss among diabetic 
population. Laser photocoagulation and intensive glycemic and blood pressure control have been 
the standard treatment approach for more than 20 years. However, in the majority of cases of 
diffuse and severe diabetic macular edema, the control of the disease is not satisfactory. The 
growing understanding of the multifactorial pathophysiology of macular edema encouraged the 
investigation of new therapies in the last decade. Both corticosteroids and vascular endothelial 
growth factor inhibitors (bevacizumab, ranibizumab, pegaptanib, and aflibercept) were widely 
studied and showed satisfactory anatomical and functional improvements with acceptable safety 
profiles. Unfortunately, some of corticosteroids’ main adverse effects and the need for multiple 
intravitreal injections remain major concerns. Intravitreal sustained drug delivery systems were 
developed to reduce these and other drug- and injection-related adverse events. Vitrectomy proves 
to be valuable only in a few selected cases, usually associated with vitreoretinal interface 
abnormalities. New laser delivery systems have been developed to reduce laser-related adverse 
events. Some experimental new drugs are also under investigation. The majority of reported studies 
have limited interest due to a short number of participants and a short follow-up. Also, their results 
are difficult to compare, due to different study designs and characteristics. The increasing number 
of reports and developing therapies shows the growing interest in this subject. A multi-modality 
approach may become the standard of care for a multifactorial disease as diabetic macular edema.  
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Diabetic retinopathy (DR) is an important cause of severe and moderate vision loss in the 
working-age population. In 10 years, nearly 90% of patients with type 1 diabetes and more than 
65% of patients with type 2 diabetes develop some form of retinopathy (Williams et al., 2004).  
Diabetic macular edema (DME), a form of DR defined as the retinal thickening involving 
the macula, is the main cause of moderate vision loss (≥15 letters lost on the Early Treatment 
Diabetic Retinopathy Study [ETDRS] visual acuity [VA] chart or a doubling of the visual angle) 
among diabetic population (Klein et al., 2009b; Williams et al., 2004).  
DME can occur at any stage of the disease progression, but incidence and prevalence tends 
to rise with the increase in duration and severity of diabetes (Williams et al., 2004). In type 1 
diabetes patients, the annual incidence of DME ranges from 0.9% to 2.3% and there is a cumulative 
incidence of 26% within 14 years of diagnosis. In 25 years, 29% of these will be presenting DME 
and 17 % will show a clinically significant macular edema (CSME) (Klein et al., 1998; Klein et al., 
2009a). In type 2 diabetes patients, the annual incidence of DME ranges from 1.25% to 1.40% and 
there is an increase in prevalence from 3% within 5 years of diagnosis to 28% after 20 years (Klein 
et al., 1995).  
DME tends to be a chronic disease, however, about 1/3 of the patients can have a 
spontaneous recovery in 6 months, without any treatment except the adequate control of glycemic 
levels (Ferris and Patz, 1984; Hikichi et al., 1997). 
Since the incidence and prevalence of diabetes are estimated to significantly increase 
during the next years (Narayan et al., 2006), the incidence of DR and consequently DME is also 
expected to rise. Therefore, in the future, it is likely that DME may be responsible for a substantial 
vision loss unless adequately treated. Aside from intensive glycemic and blood pressure control, for 
more than 20 years the standard of care has been laser photocoagulation. Laser proved to prevent 
further vision loss but unfortunately visual improvement is rare. This problem encouraged the 
search for other treatment modalities, and alternative therapies, such as intravitreal triamcinolone 
acetonide (IVTA) and vascular endothelial growth factor (VEGF) inhibitors, have been recently 
investigated in numerous clinical trials. 
Thereby, this review aims to evaluate where we stand in terms of effectiveness and safety 
of these new treatment modalities and predict how treatment guidelines may change in the next 
years. 
2 Definitions and classifications 
The ETDRS defined DME as the thickening of the retina and ⁄ or presence of hard exudates 
within one disc diameter of the center of the macula (ETDRS, 1985, 1987). The study also 
proposed the term clinically significant macular edema to characterize the severity of macular 
edema for treatment guidelines proposes. Macular edema is said to be clinically significant when 
presenting: retinal thickening at or within 500 µm of the macular center; and/or hard exudates at or 
within 500 µm of the macular center if associated with adjacent retinal thickening; and/or a zone or 
 
 
zones of retinal thickening greater than 1 disc diameter in size, at least part of which is within 1 
disc diameter of the macular center.  
Classically, DME is classified into focal or diffuse, according to the leakage pattern seen 
on the fluorescein angiogram (Kang et al., 2004). In focal DME, there are points of retinal 
hyperfluorescence due to focal leakage from microaneurysms, usually found within areas of focal 
retinal edema and commonly surrounded by rings of hard exudates. In diffuse DME, the 
fluorescein angiogram shows areas of diffuse leakage due to intraretinal outflow from a dilated 
retinal capillary bed and/or intraretinal microvascular abnormalities and/or (in severe cases) from 
arterioles and venules without foci of leaking microaneurysms. In addition, cystoid macular edema, 
which results from a generalized breakdown of the inner blood retinal barrier, with fluid 
accumulation in the outer plexiform layer, can also be present and associated to the diffuse type. 
With the appearance of new imaging techniques, such as the optical coherence 
tomography, a quantitative classification of the edema was possible. Measurements of retinal 
thickness and retinal volume have revolutionized the classification. In the initial classification, 
there were 3 basic structural changes of the retina: retinal swelling, cystoid edema and serous 
retinal detachment (Otani et al., 1999). Posteriorly, it was modified into: type 1 with foveal 
thickening with homogenous optical reflectivity in the entire layer of the retina; type 2 with foveal 
thickening and a distinct decrease in the optical reflectivity of the outer retinal layer; type 3 with 
foveal thickening with subretinal fluid accumulation; type 3 is further divided into type 3A if no 
vitreofoveal traction is present and type 3B if vitreofoveal traction is present (Kang et al., 2004). 
Further investigation brought a new classification with five different morphologic patterns: diffuse 
retinal thickening; cystoid macular edema; serous retinal detachment without posterior hyaloidal 
traction; posterior hyaloidal traction without tractional retinal detachment; and posterior hyaloidal 
traction with tractional retinal detachment. In addition, mix patterns can arise from co-existence of 
at least two of these basic patterns in the same eye (Kim et al., 2006). 
3 Pathophysiology 
Much is already known about the pathophysiology of DME, but we are still far from fully 
understanding it. It is clear that the mechanism is multifactorial and very complex. Several 
angiogenic, inflammatory and oxidative stress overlapping and inter-relating pathways have been 
implicated. It is also clear that they are directly or indirectly triggered by chronic hyperglycemia, 
recognized as the primary insult, and converge into a final common pathway that results in macular 
edema. This last step is the disruption of the blood-retinal barrier.  
The blood-retinal barrier has two components: the outer barrier is formed by retinal 
pigment epithelium (RPE) cells tightly connected by tight junctions (zonula occludens and 
desmosomes); the inner barrier is formed by retinal vascular endothelial cells tightly connected by 
tight junctional complexes (occludins and claudins) and glial cells, such as Müller cells. The 
disruption of the blood-retinal barrier occurs due to the compromise of at least one barrier 
component, leading to an increase of vascular leakage into the neurosensory retina that exceeds the 
removal of fluid from the retinal tissue into the systemic circulation (a process that can also be 
impaired), causing an accumulation of fluid in the intraretinal layers of the macula. This increase of 
 
 
permeability is due to leakage between retinal vascular endothelium or RPE (allowed by junction 
proteins disruption and cell loss), up-regulation of vesicular transport, or/and increase of surface 
membranes fenestrations of retinal vascular endothelium and RPE (Bhagat et al., 2009; Ehrlich et 
al., 2010; Singh and Stewart, 2009).  
Multiple factors have been implicated in the network of processes that lead to blood-retinal 
barrier disruption: free radicals, advanced glycation endproducts, protein kinase C beta, hepatocyte 
growth factor, fibroblast growth factor, insulin-like growth factor-1, metalloproteases, histamine, 
tumor necrosis factor, intercellular adhesion molecule-1, interleukins (1, 6, and 8), prostaglandins, 
renin, angiotensin II, and VEGF-A. They are produced mainly by and act on the cellular elements 
that form and support the blood-retinal barrier. Microaneurysms (resulting from vascular wall 
weakening, usually due to pericyte loss), altered blood flow, retinal leukostasis, retinal ischemia, 
retinal hypoxia, and vitreoretinal interface abnormalities also play a role (Bhagat et al., 2009; 
Ehrlich et al., 2010; Elbendary and Shahin, 2011; Singh and Stewart, 2009). 
The findings of glucose-mediated enhanced leukocyte-endothelial cell interaction and 
leukocyte activation, mainly through the increase of intercellular adhesion molecule-1 expression 
induced by inflammatory and pro-inflammatory mediators (such as transforming growth factor-b, 
tumor necrosis factor α, interleukin 6, protein kinase C beta, monocyte chemotactic protein-1, 
VEGF, and nuclear factor-kappa-B), has led to the recognition of DME and DR as a state of low-
grade inflammation (Bhagat et al., 2009; Ehrlich et al., 2010; Funatsu et al., 2009; Singh and 
Stewart, 2009). For this reason, anti-inflammatory agents have been tried as a treatment option. 
VEGF has proven to be a very important mediator in the pathophysiology of DME, 
especially the VEGF-A165 isoform. It is a powerful angiogenic factor produced by cellular 
elements that form and support the blood-retinal barrier such as Müller cells, RPE cells and 
endothelial cells, and is up-regulated by hypoxia, hyperglycemia and several mediators (such as 
insulin-like growth factor 1, interleukin-6, and protein kinase C beta). VEGF increases vascular 
permeability by both up-regulation of vesicular transport and direct and indirect disruption of tight 
junctions. In addition, it also has pro-inflammatory properties through the induction of intercellular 
adhesion molecule-1expression. Due to its major role, VEGF has become an important therapeutic 
target (Bhagat et al., 2009; Ehrlich et al., 2010; Singh and Stewart, 2009). 
On the other hand, structural changes of the vitreous gel, particularly the posterior cortical 
vitreous, of the posterior hyaloid, and of the internal limiting membrane (ILM) are likely to play a 
role in the pathogenesis of DME, since their presence is associated with DME exacerbation and 
persistence. These vitreoretinal interface abnormalities are thought to induce vitreomacular 
traction, exacerbating the macular edema or interfering with its resolution when treating. 
Accumulation of advanced glycation endproducts has been implicated in posterior cortical vitreous 
and ILM structural changes. A thick taut posterior hyaloid seems to occur due to the infiltration of 





4 Glycemic and blood pressure control 
Hyperglycemia and hypertension are well known as major systemic risk factors for DME. 
The strict control of blood pressure and glycaemia reduces the incidence and progression of DR 
and DME. 
With an intensive treatment of diabetes, the risk of developing retinopathy is reduced in 
76% (reducing 31% for each 1% decrement in HbA1c). In the same manner, CSME is reduced by 
more than 50%. The progression of retinopathy is also decelerated, by at least a half, and the 
frequency of photocoagulation treatments also decreases in 9 years (DCCT, 1993; Stratton et al., 
2000; White et al., 2008). 
Tightly controlled blood pressure reduces in at least 50% the moderate vision loss in 9 
years. Also, a decrease of 10 mmHg in systolic blood pressure leads to an 11% reduction in 
photocoagulation or vitreous hemorrhage. Apparently, there is no lower level of blood pressure 
below which no benefit can be obtain (Adler et al., 2000). 
Simultaneous tight control of blood pressure and blood glucose is very likely to have an 
addictive effect. The glycemic levels should be controlled to get and maintain an HbA1c of 6% or 
less and the blood pressure control should aim for a systolic pressure of 130 mmHg or less. 
(Stratton et al., 2006). 
5 Laser photocoagulation 
5.1 Mechanism of action 
The specific mechanisms by which photocoagulation reduces DME are still unknown, but 
several hypotheses have been proposed over the years. The general idea is that laser destroys RPE 
cells and the adjacent blood–retina barrier; in response, the adjacent RPE cells release trophic 
factors and cytokines, and both these cells and endothelial cells in retinal capillaries proliferate and 
replace the destroyed ones, allowing the recovery of the blood–retina barrier within a few weeks 
(Matsumoto et al., 1994; Wilson et al., 2003). At the same time, the oxygenation of the inner retina 
improves (Stefansson, 2001) and, in combination with anti-angiogenic factors released by the RPE 
cells (Ogata et al., 2001; Yoshimura et al., 1995), leads to retinal vasoconstriction and VEGF 
reduction, with a consequent leakage decrease (Wilson et al., 2003). This improvement in oxygen 
may, in part, be due to the destruction of a few highly oxygen-dependent optical cells (Stefansson, 
2001).  
5.2 Techniques 
Several types of laser wavelengths are available for photocoagulation. For the treatment of 
DME, the wavelengths mainly used are the green wavelengths (Argon [514 µm] and doubled 
frequency Nd: YAG [532 µm]) and the red/infrared wavelengths (Krypton [647 µm] and Diode 
[810 µm]). Of them all, the most used and studied is the argon green laser. Compared with the 
“green” lasers, the “red” lasers are less absorbed by the hemoglobin, which can useful in the 
presence of an intraocular hemorrhage, and produce less damage to the inner retina.  
 
 
Laser treatments can be applied in different patterns and in pulses with different 
characteristics. The standard treatment guidelines were provided by the ETDRS (ETDRS, 1987). 
Patients with mild to moderate nonproliferative DR are treated with laser therapy, as soon as 
CSME is detected. The focal pattern is preferred for leaking microaneurysms, while the grid 
pattern is preferred for diffuse areas of macular edema more than 500 µm from the central macula 
or optic nerve and for nonperfused thickened retina. For proliferative DR, and selected cases of 
severe nonproliferative DR, once CSME is detected, the option is combination of scatter laser 
photocoagulation and focal laser photocoagulation. It is recommended that, whenever possible, 
laser treatment of DME should precede panretinal photocoagulation by at least 6 weeks, once 
macular exudation can increase after pan-photocoagulation. Patients should be scheduled every 3-4 
months and retreatment is based on the persistence or recurrence of thickening and leakage. In 
patients with no visual symptoms that meet treatment guidelines, laser therapy should be 
considered to prevent an eventual vision loss. However, the decision should be based on several 
factors, such as the proximity of the exudates to the fovea, the status of the fellow eye, anticipated 
cataract surgery, and retinopathy approaching high-risk proliferative DR. In cases of treatment 
delay, a close follow-up is required for early progression detection and treatment. 
The technique commonly used in clinical practice is the modified ETDRS treatment, a 
modification of the original technique used in the ETDRS, which basically consists of both focal 
closure of aneurysms and applications of light grid photocoagulation. 
The development of subthreshold micropulse diode laser system allows the delivery of 
multiple pulses of very short duration (0.1 ms), in either a focal or grid pattern (Berger, 1997; 
Bhagat et al., 2009). The energy provided by each pulse is much lower than the one provided by 
the conventional laser photocoagulation. This lower energy is less dispersed to the surrounding 
structures, thus limiting most of the thermal damage to the target site (the RPE), minimizing the 
thermal damage on the photoreceptors and choriocapillaris. Therefore, most of the adverse effects 
of the conventional laser photocoagulation, such as scotomas, are avoided. Also, there are some 
economic advantages: it requires no cooling system, is more compact and cheaper to maintain, and 
has a longer operating time (Brancato et al., 1988). However, it presents some practical difficulties: 
as it leaves no visible scars, it is difficult to identify prior burns, making the placement of a grid or 
a retreatment potentially inaccurate. Therefore, a careful planning is required and fundus 
autofluorescence can be a useful tool when doing it. 
Automated photocoagulation systems so far proved to be not very practical. In contrast, a 
semiautomated patterned scanning laser photocoagulator, commonly known as PASCAL®, has 
gained the interest of physicians, since it gives control over the treatment, unlike the fully 
automated systems. It usually uses Argon or DF-Nd: YAG wavelengths and can deliver one or 
multiple spots in a predetermined pattern in a single burst, with a pulse duration as fast as 10 ms. 
The advantages over conventional system are increased uniformity and precision of spot 
placement, reduction of treatment duration, and potential increase in safety due to reduced thermal 
diffusion (Blumenkranz et al., 2006). Due to shorter pulses, and therefore lower energy, lesions are 
usually barely visible, but they can be assessed by fourier-domain optical coherence tomography 




Laser photocoagulation is mostly associated with vision stabilization, preventing further 
vision loss. The first major study demonstrating the efficacy of laser photocoagulation was the 
ETDRS study. This study concluded that focal argon laser photocoagulation could reduce the risk 
of moderate visual loss in eyes with CSME and mild to moderate nonproliferative DR, by at least 
50%, for as long as 3 years. However, a visual improvement equal or superior to 15 letters was rare 
(ETDRS, 1985, 1987). In addition, no evidence has been found regarding any efficacy difference 
between the different wavelengths, in term of visual improvement and macular edema reduction 
(Akduman and Olk, 1997; Bandello et al., 2005; Casswell et al., 1990; Gupta et al., 2001; 
Khairallah et al., 1996; Olk, 1990; Tewari et al., 1998). 
Unlike focal DME, diffuse DME tend to be more refractory to laser photocoagulation. A 
few studies suggested that the modified ETDRS treatment could effectively improve VA in diffuse 
DME eyes, although the effect persisted only for about 2 years (Ladas and Theodossiadis, 1993; 
Olk, 1986). When compared with the modified ETDRS treatment, a mild macular grid laser 
technique revealed a trend to worse outcomes after 1 year (Fong et al., 2007).  
The subthreshold micropulse diode laser is as effective as the modified ETDRS treatment 
and the Nd:YAG laser photocoagulation in both vision improvement and macular edema reduction, 
at least for the first year (Figueira et al., 2009; Kumar et al., 2010; Laursen et al., 2004; Venkatesh 
et al., 2011; Vujosevic et al., 2010). According to a nonrandomized study, the treatment of diffuse 
CSME with subthreshold micropulse diode laser can resolve the macular edema in 92% in 2 years 
and stabilize VA in about 80% of the patients for at least 3 years (Sivaprasad et al., 2007). One 
recent study suggests that in 1 year, a high-density micropulse diode laser technique can provide 
superior anatomic and functional outcomes than the modified ETDRS treatment (Lavinsky et al., 
2011). These results suggest that patients are probably overtreated with the conventional laser 
therapy. 
A retrospective study shows promising results for DME with PASCAL®, demonstrating 
comparable outcomes to the standard focal laser treatment in a 4 months follow-up period (Jain et 
al., 2010). 
Several clinical features have been shown to predict visual outcomes after 
photocoagulation. The ones that predict a poorer visual outcome are diffuse macular edema with 
central-involvement, diffuse fluorescein leakage, macular ischemia, hard exudate deposits in the 
fovea, marked cystoid macular edema, and greater baseline retinal volume. In contrast, a worse 
baseline VA is associated with more frequent VA improvement. Prior macular or panretinal 
photocoagulation, demographic factors, diabetes-related factors (type, duration, HbA1c, systolic or 
mean arterial blood pressure), anomalies detected by optical coherence tomography (cystoid 
abnormalities, subretinal fluid, vitreoretinal abnormalities), and fundus photograph findings 
(retinopathy severity, hemorrhage, microaneurysms, exudates, surface wrinkling) were not 





The adverse events that occur are, directly or indirectly, caused by thermal damage to the 
retina and/or choroid and can compromise quality of vision, and thus cause symptomatic visual 
loss, especially with repeated treatments. The main adverse events reported are scars. Its 
progressive enlargement may lead to decreased color vision and contrast sensitivity and/or loss of 
central vision, central and paracentral scotomas, choroidal neovascularization, and subretinal and 
macular fibrosis. In addition, accidental burns of the macular center and RPE metaplasia have also 
been reported (Bhagat et al., 2009; Thompson and Ip, 2004). Very short duration laser pulses 
minimize the risk for these complications. 
6 Corticosteroids  
6.1 Mechanism of action 
The exact mechanism of action of corticosteroids in the treatment of macular edema is 
unknown. It seems that corticosteroids reduce vascular leakage in several ways: increasing tight-
junction proteins (Antonetti et al., 2002); reducing the expression of VEGF (Edelman et al., 2005; 
Sears and Hoppe, 2005), interleukins and other cytokines (Sohn et al., 2011), and prostaglandins 
(by inhibition of the cyclooxygenase) (Martidis et al., 2002); and suppressing the influx of 
leukocytes into the retina, reducing leukostasis (Tamura et al., 2005). 
6.2 Techniques of delivery 
Treating DME with systemic corticosteroids is not practical because its prolonged systemic 
use is harmful to the metabolic control. Local ocular delivery is therefore the best option. 
Corticosteroids have been tested in different doses and administration routes (periocular and 
intravitreal injections and intravitreal slow drug release devices). 
Intravitreal injections provide an excellent delivery to the retina and choroid with low 
systemic exposure, but the levels tend to decrease fairly quickly, requiring frequent injections, 
which is not convenient.  
A less invasive and consequently thought to be safer alternative to intravitreal injections 
are peribulbar injection, which can be performed using anterior subtenon/subconjunctival, posterior 
subtenon, and retrobulbar approaches. Some authors consider this administration route not ideal to 
obtain a therapeutic dosage in the retina, while others demonstrate that a correct application of the 
injection allows therapeutic quantities in the macular area (Freeman et al., 1987; Thomas et al., 
2006). There are some evidences that a superotemporal placement technique may lead to a more 
accurate placement of drugs near the macula (Freeman et al., 1987).  
Intravitreal sustained drug delivery systems are another alternative that has gained some 
interest in recent years. These allow the continuum delivery of low doses of corticosteroids over 




6.3 Intravitreal injections (triamcinolone acetonide) 
The magnitude of the effect of IVTA is dose related: higher doses lead to a more 
pronounced and prolonged treatment response. However, among lower doses (from 2 to 6 mg) the 
therapeutic differences are not significant (Audren et al., 2006b; Beck et al., 2009; Kim et al., 
2008; Lam et al., 2007b; Network, 2008; Spandau et al., 2005). Despite the optimal dose for the 
DME treatment is not yet defined, the 4 mg dose has been empirically chosen in the majority of the 
studies. 
The therapeutic effects provided by a single IVTA (4 mg) injection are transient, not 
lasting more than 6 months. Therefore, additional injections are required to maintain the 
improvements over time. Visual improvement can occur in 3-4 weeks, but after a maximum gain, it 
gradually deteriorates (Kang et al., 2006; Lam et al., 2007a). Unfortunately, the VA continues to 
deteriorate with additional injections, and, eventually, around the 16th month after the first injection 
it can become worse than at baseline (Beck et al., 2009; Kang et al., 2006; Lam et al., 2007a; 
Network, 2008). Some evidences suggest that this drop of efficacy may not be only the result of 
corticosteroid-induced cataract progression (Beck et al., 2009; Network, 2008). On the other hand, 
the anatomical performance is much better. Although a single injection can only sustain a 
significant reduction for little more than 3 months (Kang et al., 2006), additional injections, 
performed as needed every 4 months, can maintain the reduction for at least 3 years (Beck et al., 
2009; Lam et al., 2007a; Network, 2008).  
In cases of persistent or recurrent DME after laser treatments, short term results are 
promising (Audren et al., 2006a; Dehghan et al., 2008; Jonas et al., 2006; Larsson et al., 2009) and 
with a retreatment regimen as needed with IVT and laser, the therapeutic effect can be extended for 
at least 5 years (Gillies et al., 2009; Gillies et al., 2006; Sutter et al., 2004). However, by itself, 
IVTA may not be enough to provide sustained benefits at long-term, at least not better than laser 
(Ockrim et al., 2008). Refractory DME with cystic changes also responds to IVTA (Dehghan et al., 
2008), even with lower dosages (1 or 2 mg) (Hauser et al., 2008); cystoid DME might beneficiate 
from a greater benefit with IVTA than the diffuse type (Kim et al., 2008).  
IVTA also shows promising results as a primary treatment (Norlaili et al., 2011). 
A few factors have been associated with the therapeutic response to IVTA. Greater 
anatomical and functional outcomes occur in eyes with worse baseline thickening and VA levels, 
respectively (Mohamed et al., 2009). Presence of macular ischemia is associated with poorer visual 
outcome (Jonas et al., 2005). The type/pattern of macular edema may also be important (Gibran et 
al., 2007). 
A nonrandomized study suggests that IVTA could be a valuable tool in DME eyes with 
serous macular detachment; although recurrence does occur, re-injections results are tend to be as 
good as the ones obtained with the initial injection (Ozdemir et al., 2005).  
Compared with laser, a regimen of multiple IVTA injections, in 4-month intervals, can 
provide superior anatomical and functional outcomes for the first 4 months. However, due to the 
progressive improvement with laser therapy and the decrease of the IVTA effect, the differences 
 
 
dissolve after the first year. Around the 16th month of treatment, laser becomes significantly 
superior, remaining that way for at least another year (Beck et al., 2009; Lam et al., 2007a; 
Network, 2008). Like IVTA in monotherapy, a combined treatment sequence of an IVTA injection 
3 to 6 weeks before the laser session, with retreatment as needed, shows better anatomical than 
functional results over time (Aydin et al., 2009; Gillies et al., 2010, 2011; Kang et al., 2006; Lam et 
al., 2007a). It also does not seem to provide significant advantages over laser monotherapy at long-
term (2 years) (Gillies et al., 2010, 2011; Lam et al., 2007a). But, some benefits can be found; the 
combined treatment allows an earlier visual recovery (Aydin et al., 2009), a more sustained visual 
improvement (Kang et al., 2006), a slower recurrence of the macular edema (Kang et al., 2006; 
Lam et al., 2007a), and a lesser need for additional injections and laser treatments (Mohamed et al., 
2009). In contrast, a concomitant association (laser immediately followed by IVTA) should be 
avoided, since it may lead to a worsening of the VA (Aydin et al., 2009). 
In cases of DME with moderate to high-risk proliferative DR, the combination of IVTA 
with standard treatment (pan-retinal photocoagulation plus macular photocoagulation) or simply 
with pan-retinal photocoagulation shows superior results over the standard treatment alone. 
However, while in moderate risk cases the therapeutic effect can be maintained for 1 year (Maia et 
al., 2009), in high risk cases the superiority can only be maintained for a much more shorter period 
(Choi et al., 2007; Mirshahi et al., 2010). In addition, IVTA can also reduce the risk of short-term 
exacerbation of macular edema (and consequent associated VA loss) after pan-retinal 
photocoagulation, at least in short-term (Googe et al., 2011). 
A small nonrandomized prospective study suggests that the adjunctive use of IVTA after 
vitrectomy should be avoided, because 1 year later the recurrence may be worse than with 
vitrectomy alone (Shimonagano et al., 2007a).  
6.4 Peribulbar injections (triamcinolone acetonide) 
Peribulbar route (by both posterior subtenon's triamcinolone acetonide injection [40 mg] 
and anterior subtenon's triamcinolone acetonide injection [20 mg]) was thought to be a good initial 
approach in eyes with mild DME and good VA. However, the results were disappointing, and 
further studies were not recommended (Chew et al., 2007). 
In more severe diffuse DME, a single posterior subtenon's triamcinolone acetonide 
injection, combined with grid laser or not, can provide anatomical and functional improvements in 
some cases, with the effects lasting little more than 3 months. However, these improvements are 
not as good and sustained as the ones provided by a single IVTA (4mg) injection (Chung et al., 
2008a; Yalcinbayir et al., 2011). On the other hand, in eyes with cystoid DME, the posterior 
subtenon injection approach seems to provide a longer effect than the intravitreal approach (Cellini 
et al., 2008) and combined with laser may provide a better chance of stabilizing vision loss than 
photocoagulation alone (Kuo et al., 2009). 
As primary treatment for diffuse DME, posterior subtenon's triamcinolone acetonide 
injection can also provide an additive effect to laser. The improvement appears more prominent 
when the baseline ETDRS score is superior to 40 letters (Tunc et al., 2005). In contrast, it presents 
 
 
no value in refractory to laser DME eyes (Bonini-Filho et al., 2005; Cardillo et al., 2005), even 
with additional injections (Entezari et al., 2005), and also as an adjuvant treatment to 
phacoemulsification (Takata et al., 2010). 
Nonrandomized studies suggest that posterior subtenon's triamcinolone acetonide injection 
may perform better in vitrectomized eyes, even if they are refractory to vitrectomy (Koga et al., 
2005; Sato et al., 2008; Wada et al., 2005). 
As for factors that influence peribulbar injections’ performance, the local of injection is 
one of the most important. It was shown that a precise placement of corticosteroids in the 
subtenon’s capsule space, in direct proximity to the macula, might influence both the effectiveness 
and the side effects of the drug. (Freeman et al., 1987; Mueller et al., 1998). Drug reflux at the time 
of the injection is also a risk factor for treatment failure (Shimura et al., 2009). 
6.5 Intravitreal delivery systems 
Retisert® (Bausch & Lomb) is a non-biodegradable delivery platform implant providing 
fluocinolone acetonide. Its implantation and removal, once drug depletion, requires a surgical 
procedure in an operating room. It is sutured to the anterior eye wall and provides a highly reliable 
and stable long-term drug delivery (Driot et al., 2004). The initial release rate is 0.60 µg/day, 
decreasing in 1 month to a stable rate of 0.3-0.4 µg/day, and its life span is about 30 months (Jaffe 
et al., 2000). This implant is currently approved for the treatment of chronic noninfectious posterior 
uveitis. Iluvien® (Alimera Sciences) consists in very small non-biodegradable cylindrical tubes that 
have a polymer matrix loaded with fluocinolone acetonide (Campochiaro et al., 2011; 
Campochiaro et al., 2010). The device is inserted into the vitreous cavity through a 25-gauge 
needle, not needing a surgical procedure or an operating room. It can deliver the drug at a rate of 
0.5 or 0.2 µg/day. When the drug supply is depleted, another one can be administered; the limit 
number of inserts that can be tolerated is unknown.  
In eyes with persistent or recurrent DME, both Retisert® (Pearson et al., 2011) and Iluvien® 
(Campochiaro et al., 2011; Campochiaro et al., 2010) can provide significant macular edema 
reduction and VA improvement for about 2 years, reflecting the drug lifespan. They also decrease 
the need of additional laser treatment. However, there are some VA fluctuations, thought to be 
related to cataract formation and extraction.  
Ozurdex® (Allergan Inc.) is a biodegradable drug delivery system that allows sustained-
release of dexamethasone. Inserted into the vitreous cavity through a 22-gauge needle, it can 
deliver the drug at a rate of 350 or 700 µg/day and its life span is about 6 months. It is approved for 
the treatment of macular edema caused by retinal vein occlusion (Haller et al., 2010). In eyes with 
persistent or recurrent DME, the significant therapeutic improvement lasts for little more than 3 
months and a release of 700 µg/day shows better efficacy than 350 µg/day (Haller et al., 2010). 
Vitrectomized patients with persistent or recurrent DME may also benefit from Ozurdex®, 




6.6 Safety of corticosteroids 
Despite the majority of the randomized studies are limited by the short follow-up and 
participant numbers, their combined evidences reveal that, in general, and regardless of the 
application route, the most common corticosteroid-related vision-threatening complications are the 
intraocular pressure (IOP) increase and the development and progression of cataract.  
With IVTA and fluocinolone acetonide intravitreal delivery systems (Audren et al., 2006a; 
Audren et al., 2006b; Aydin et al., 2009; Beck et al., 2009; Campochiaro et al., 2011; Campochiaro 
et al., 2010; Choi et al., 2007; Dehghan et al., 2008; Gillies et al., 2011; Gillies et al., 2009; Jonas 
et al., 2006; Kang et al., 2006; Lam et al., 2007a; Lam et al., 2007b; Larsson et al., 2009; Lee et al., 
2009; Maia et al., 2009; Ockrim et al., 2008; Pearson et al., 2011; Spandau et al., 2005) the 
elevation of IOP is usually mild to moderate, transient and controllable with topical 
antiglaucomatous medication, without future sequels. However, in some cases it can lead to 
secondary glaucoma and surgery might be required. The risk can reach 80% or more in 5 years and 
the first episode can occur in the first months (usually in the 2nd). Higher doses tend to increase the 
probability of IOP elevation and glaucoma; this might be the reason for the higher risk associated 
to Retisert® compared with Iluvien®. As for the progression of cataracts, it is progressive and, in 
most cases, only evident after 1 year and/or multiple doses. At least 2/3 end up requiring cataract 
surgery in 5 years, which can, in a few patients, exacerbate macular edema, leading to poorer 
outcomes. Unlike the elevation of IOP, cataract development seems less dose-dependent. 
Regarding the dexamethasone delivery system, the incidence of increased IOP seems lower than 
with IVTA, however, study follow-up was too short to allow long-term conclusions regarding 
incidence of both IOP increase and cataract progression (Haller et al., 2010). 
Other adverse effects reported with intravitreal approaches are: vitreous hemorrhage, 
pruritus, vitreous floaters, subconjunctival hemorrhage, retinal detachment, corneal epithelial 
defect, abnormal sensation in the eye, eye pain, and endophthalmitis. They are generally transient 
and thought to be related to the implantation and injection procedures.  
High-dosage IVTA may not necessarily have a higher side effects profile than low-dosage 
IVTA (Jonas et al., 2006). In contrast, multiple injections predispose to the cumulative risk of 
injection-related and drug-related (Gillies et al., 2009; Jonas et al., 2003) complications. 
No systemic drug-related adverse events have been reported. In fact, triamcinolone 
acetonide is barely detected in the serum after an intravitreal injection of 20 mg (Degenring and 
Jonas, 2004). 
The peribulbar approach is clearly less invasive than the intravitreal approaches and shows 
fewer vision-threatening complications (Cellini et al., 2008; Chung et al., 2008a). In short-term, the 
elevation of IOP seems lower than with IVTA, although the association of posterior approach with 
IOP elevation is less certain (Chew et al., 2011). Short follow-up period unable cataract discussion, 
with the exception of the anterior approach, which has been associated with an increased risk of 
cataract development, compared with laser and posterior peribulbar approach. Other potential 
injection- or infusion-related complications are: ptosis, accidental injection directly into the 
 
 
choroidal or retinal circulation, perforation of the ocular bulb, occlusion of the central retinal 
artery, blepharoptosis, orbital fat atrophy, strabismus, conjunctival necrosis and ulceration, and 
endophthalmitis (Agrawal et al., 2003; Cellini et al., 2008; Chew et al., 2007; Chew et al., 2011). 
These complications are rare when the injection is properly given. 
7 Anti-VEFG Therapy 
7.1 Mechanism of action 
VEGF plays a key role in the pathophysiology of DME. Thereby, VEGF blockage became 
an attractive therapeutic approach. After the first evidences that VEGF inhibition could effectively 
prevent experimental diabetic blood–retina barrier breakdown and also revert DME once it has 
occurred, VEGF inhibitors have been studied, in the last decade, as a therapeutic option for DME.  
Bevacizumab, ranibizumab, pegaptanib and aflibercept bind to VEGF, preventing 
interaction with its receptors (VEGFR1 and VEGFR2) on the surface of endothelial cells, thereby, 
nullifying its biological effect.  
7.2 Intravitreal bevacizumab   
Bevacizumab (Avastin®, Genentech Inc.) is a full-length recombinant humanized 
monoclonal IgG1 antibody directed at all isoforms of VEGF-A. Originally used in the treatment of 
various cancers, it is being used off-label as a treatment for DME. 
The optimal dosage and algorithm for DME treatment are still not defined, but the majority 
of studies use a 1.25 mg dose. There is no evidence that a higher dose of 2.5 mg provides a 
significantly superior efficacy (at least in the first 6 months), so the lower dose is recommended 
(Lam et al., 2009; Scott et al., 2007). A single intravitreal bevacizumab (IVB) (1.25 mg) injection 
can reduce the macular edema in 24h, but the VA needs about 1 week to significantly improve 
(Sonoda et al., 2011). The effect lasts for little more than 12 weeks (Isaac et al., 2012; Wang et al., 
2011), therefore, multiple injections are needed to sustain the effects for longer periods 
(Michaelides et al., 2010; Soheilian et al., 2009). 
When compared with standard laser treatment, IVB demonstrates a significantly greater 
macular edema reduction (Scott et al., 2007). When in combination, focal laser applied 3 weeks 
after IVB does not seem to provide any additional short-term benefit over IVB monotherapy (Scott 
et al., 2007), but grid laser, also applied 3 weeks after IVB, is able to maintain the functional and 
anatomical improvements of a single IVB injection for a longer period of time in eyes with diffuse 
CSME (Solaiman et al., 2010). 
In short-term, both IVTA (2 and 4 mg) and combination of IVB (1.25 mg) and IVTA 
(2mg) are anatomically and functionally more efficient than IVB (1.25 mg) alone (Isaac et al., 
2012; Lim et al., 2012). However, after 1 year of treatment no significant differences can be seen 
between them, so IVB/IVTA association provides no significant additional benefit over IVB 
monotherapy (Lim et al., 2012; Wang et al., 2011). In contrast, the improvements may persist 
 
 
longer with IVB alone than with IVB/IVTA association (36 weeks vs. 12 weeks), with or without 
additional injections (Soheilian et al., 2009).  
Similar performance for IVB (compared to and/or associated to IVTA or laser) is found in 
treatment naïve eyes (Faghihi et al., 2008; Marey and Ellakwa, 2011; Shahin and El-Lakkany, 
2010; Soheilian et al., 2007) and in eyes with refractory/persistent DME, even when center-
involving (Ahmadieh et al., 2008; Michaelides et al., 2010; Paccola et al., 2008; Synek and Vesely, 
2011). However, there are some evidences that in treatment naïve eyes it can be more effective 
than in eyes that had any prior treatment (Lam et al., 2009; Scott et al., 2007).  
A prospective nonrandomized study (Kook et al., 2008) suggests that IVB can even be 
benefic in cases of chronic diffuse ischemic DME, but the preexisting macular ischemia limits the 
potential treatment benefits (Chung et al., 2008b). 
IVB can also be useful in preventing the exacerbation of macular edema in diabetic 
patients undergoing cataract surgery. A single IVB injection has the potential not only to prevent 
the increase, but also reduce the macular edema and improve the VA, for at least 6 months 
(Cheema et al., 2009; Lanzagorta-Aresti et al., 2009; Takamura et al., 2009), although, in some 
cases, the positive effect lasts for a shorter period of time (Fard et al., 2011). 
7.3 Intravitreal ranibizumab   
Ranibizumab (Lucentis®, Novartis Pharma AG and Genentech Inc.) is a Fab fragment of a 
full-length recombinant humanized monoclonal IgG1 antibody that binds to the receptor-binding 
site of active forms of VEGF-A. As the Fab derivate of bevacizumab, its molecular weight is a 
fraction of the bevacizumab’s weight (~48 kilodaltons vs. ~149 kilodaltons, respectively), which 
may explain its shorter intravitreal half-live in animal studies (3.2 vs. 5.6 days) (Stewart et al., 
2012).  
Already approved for the treatment of macular edema associated with retinal vein 
occlusion and age-related macular degeneration, it was recently also approved by the European 
Medicines Agency for the treatment of DME, based on evidence from the RESOLVE (Massin et 
al., 2010) and RESTORE (Mitchell et al., 2011) trials. 
A single intravitreal ranibizumab (IVR) (0.5mg) injection is capable of reduce macular 
edema in about 1 hour and significantly improve the VA in 24 hours, although the maximum effect 
is only achieved after approximately 14 days (Querques et al., 2009b). After 1 month the effect 
starts to decrease, so additional injections are required to maintain the therapeutic levels. In 
general, a regimen of multiple injections of IVR, in a minimal interval of 4 weeks, can provide 
significant VA increase and macular edema reduction for at least 2 years (Massin et al., 2010; 
Mitchell et al., 2011). These results are also observed in patients with recurrent or persistent DME 
(Nguyen et al., 2009; Nguyen et al., 2010). 
A small retrospective study suggests that despite no significant difference between one 
injection of IVB and IVR in terms of visual improvement (4.5 vs. 6 ETDRS letters, p=0.58, 
 
 
respectively), a difference might exist in the degree of macular edema reduction, being greater with 
IVR (41 vs. 100#µm, p=0.005) (Ozturk et al., 2011). 
The combination with laser photocoagulation does not seem to provide any functional or 
anatomical advantage over IVR monotherapy (Mitchell et al., 2011; Nguyen et al., 2009; Nguyen 
et al., 2010). In fact, in some cases, it can lead to a slower visual improvement rate compare with 
IVR alone (Nguyen et al., 2009; Nguyen et al., 2010). On the other hand, additional laser allows a 
decrease in the need for additional injections to control the edema. Delaying in 6 months the 
beginning of the laser sessions, instead of starting it closer to the IVR treatment, also does not seem 
to result in any difference (Elman et al., 2010; Elman et al., 2011). Compared with laser alone, 
IVR, associated or not with laser, demonstrates therapeutic superiority (Elman et al., 2010; Elman 
et al., 2011; Mitchell et al., 2011; Nguyen et al., 2009; Nguyen et al., 2010). 
In addition, IVR may provide some short-term benefits in eyes receiving pan-retinal 
photocoagulation for DR and laser for DME by reduce the risk of short-term exacerbation of 
macular edema (Googe et al., 2011). 
The approval of ranibizumab by the European Medicines Agency led a panel of experts to 
elaborate the first guidelines for its clinical use. Their recommendation is to use ranibizumab in 
monotherapy when visual impairment due to center-involving DME. Center-involving DME with 
no vision loss and no center-involving DME cases should follow the ETDRS guidelines. Injections 
are given on a monthly basis until normal VA or VA stability is achieved. If VA deteriorates again 
after treatment interruption, monthly injections should be reinitiated until a new stabilization is 
achieved. Addition of laser is neither recommended nor rejected; for now it is up to the physician’s 
discretion. Non-responders to the therapy should discontinue it and try other treatment options 
(Bandello et al., 2012). Updates to these guidelines may occur as more results from longer-term 
studies become available.  
7.4 Intravitreal pegaptanib sodium    
Pegaptanib (Macugen®, Pfizer Inc. and OSI Pharmaceuticals Inc.) is a VEGF aptamer that 
binds to the VEGF-165 isomer inhibiting the interaction with its receptors. It is an approved 
treatment for age-related macular degeneration and an off-label treatment for DME. 
In terms of dosage, there are some indications that a 0.3 mg can be more effective than 1 
and 3 mg, although differences between 0.3 and 1 mg are very small (Cunningham et al., 2005). 
In patients with DME, center-involving or not, a regiment of multiple injections of 
pegaptanib (0.3 mg), 6 or more weeks apart, with the possibility of focal/grid photocoagulation 
after the 18th week, demonstrates significantly better outcomes than sham (Loftus et al., 2011; 
Sultan et al., 2011), even as primary therapy (Cunningham et al., 2005). The visual benefits appear 
to be more outstanding than the anatomical ones. This beneficial visual effect can be observed in 6 
weeks after the first injection and persists for at least 2 years, although slightly better during the 1st 
year of treatment (Sultan et al., 2011). Also, pegaptanib decreases the need for additional laser 
therapy (Sultan et al., 2011).  
 
 
A retrospective study suggests that, as primary therapy, pegaptanib, in 6 month, may be 
significantly superior to both laser and combination of pegaptanib with laser (Querques et al., 
2009a). 
7.5 Intravitreal aflibercept 
Aflibercept (VEGF Trap-Eye®, Regeneron Pharmaceuticals Inc. and Bayer Healthcare 
Pharmaceuticals) is a fully human recombinant fusion protein composed by the VEGF receptors 
domains and the Fc region of human IgG1, which binds to all VEGF-A isoforms and also to 
placental growth factor (Holash et al., 2002). Animal studies suggest that it has theoretical 
advantages over ranibizumab and bevacizumab, including a longer life span and a higher binding 
affinity to VEGF-A.  
The DA VINCI phase 2 Study has recently shown some primary good results using 
aflibercept in DME patients. VEGF Trap-Eye (0.5 and 2 mg), in various retreatment schedules, 
shows significant and clinically relevant VA improvement, as well as macular edema reduction, 
which are superior to laser, for at least 6 months (Do et al., 2011). 
7.6 Safety of anti-VEFG Therapies  
The overall safety profile is similar between bevacizumab, ranibizumab and pegaptanib 
sodium and consistent with that observed in patients with neovascular age-related macular 
degeneration treated with these VEGF inhibitors (Brown et al., 2006; Singerman et al., 2008).  
The incidence of drug-related ocular adverse effects is low, even with multiple injections. 
The great majority of reported ocular adverse is transient, mild to moderate in severity and 
considered injection-related (Ahmadieh et al., 2008; Cunningham et al., 2005; Do et al., 2011; 
Elman et al., 2010; Elman et al., 2011; Faghihi et al., 2008; Googe et al., 2011; Lam et al., 2009; 
Massin et al., 2010; Michaelides et al., 2010; Mitchell et al., 2011; Paccola et al., 2008; Scott et al., 
2007; Shahin and El-Lakkany, 2010; Soheilian et al., 2009; Sultan et al., 2011; Wang et al., 2011). 
The most frequent are eye pain (up to 31% reported), conjunctival hemorrhage (up to 22%), and 
punctate keratitis (up to 18%). Other adverse effects also reported, are endophthalmitis (0.08-
0,4%/injection), retinal detachment (<1%), vitreous hemorrhage (up to 5%), cataract formation and 
progression (up to 14%), IOP elevation (up to 17%), and transient mild anterior chamber reaction 
(up to 20%). 
Regarding systemic side effects, the use of systemic VEGF inhibitors has been associated 
to cardiovascular events, cerebrovascular accidents, hypertension, and thromboembolic events. 
Because of the compromised blood–retinal barrier in diabetic patients, there is a potential higher 
risk of the passage of these drugs into the systemic circulation (Bhisitkul, 2006; Simo and 







There are reports in the literature of lower risk of macular edema development in diabetic 
patients with a posterior vitreous detachment (PVD) (Nasrallah et al., 1988), cases of reabsorption 
of macular edema after a spontaneous PVD (Hikichi et al., 1997) and a successful first trial with 
vitrectomy in 10 patients with DME and thickened taut posterior hyaloid (Lewis et al., 1992). 
Consequently, intraocular interventions through pars plana vitrectomy have been proposed as an 
alternative approach for DME treatment.  
Induction of PVD by removal or detachment of posterior hyaloid is the main intervention. 
Triamcinolone acetonide can be used to facilitate the identification of vitreous remnants. Another 
technique, usually used after PVD induction, is the ILM peeling, a process that can be facilitated by 
the use of dyes (such as indocyanine green, trypan blue and, more recently, brilliant blue). 
8.2 Mechanism of action 
The mechanism by which vitrectomy may work is not fully understood. It is speculated that 
PVD removes local exacerbation factors, such as vitreous traction, and improves oxygen 
concentration on retinal cells. Also, the absence of the vitreous gel is thought to increase the 
transport of cytokines (such as VEGF) from the retina into the vitreous cavity (Stefansson, 2001, 
2009).  
It is speculated that normal ILM acts as a selective membrane. In DME it gets thicker, thus 
reducing its permeability (Saravia, 2011). With its removal, this disturbance could be resolved, 
therefore helping the resolution of the macular edema, for example, by further speeding up the 
clearance of cytokines from the retina. Also, absence of ILM may activate the repair mechanisms 
of Müller cells and can eliminate a reservoir of growth factors in residual vitreous cortex that 
remains adherent to the ILM after surgical vitreous separation (Hoerauf et al., 2011; Sonoda et al., 
2004). 
8.3 Efficacy 
In general, the vitrectomy results in DME eyes are not satisfactory. It has been suggested 
that benefits may be limited to patients with vitreomacular traction and/or taut thickened posterior 
hyaloid (Laidlaw, 2008). 
In diffuse DME cases with no evidence of macular traction, regardless the technique, the 
benefits are limited and appear slowly (Bardak et al., 2006; Doi et al., 2012; Kumar et al., 2007). In 
cases of persistent DME after laser therapy, vitrectomy, with or without ILM peeling, can provide 
some benefits, mainly in younger patients. However, the improvement, eventually superior to laser, 
persists for no longer than 1 year (Bahadir et al., 2005; Stolba et al., 2005; Yanyali et al., 2006), 
after which laser seems to provide better results (Patel et al., 2006a; Thomas et al., 2005). 
 
 
Curiously, some retrospective studies, unlike randomized studies, suggest better visual 
outcomes with vitrectomy in eyes with diffuse DME with no macular traction, with the 
effectiveness maintained for years (Kumagai et al., 2009; Shimonagano et al., 2007b). 
It is not clear if ILM peeling is necessary. Several studies report no significant benefit over 
PVD induction alone (Bahadir et al., 2005; Bardak et al., 2006; Figueroa et al., 2008; Mochizuki et 
al., 2006; Patel et al., 2006b; Shiba et al., 2009). However, in cystoid-type DME cases, while PVD 
induction alone seems to provide no benefit, adding ILM peeling may lead to a reduction of the 
macular edema and a better VA stabilization; in eyes with preexisting PVD, ILM peeling may 
actually increase the VA (Hoerauf et al., 2011). 
According to a nonrandomized study, a few factors may predict the therapeutic response to 
vitrectomy. Greater VA improvement was associated with worse baseline VA and epiretinal 
membrane removal. Greater reduction in macular thickness was associated with worse baseline 
VA, greater preoperative retinal thickness, removal of ILM, and vitreoretinal abnormalities (Flaxel 
et al., 2010). 
8.4 Safety 
In surgery there is always a potential risk of complications. The most frequently reported 
complications related to vitrectomy, with or without ILM removal, are cataract formation (usually 
not evident before the 1st year), retinal tears, (rhegmatogenous) retinal detachments, epiretinal 
membrane formation, vitreous hemorrhage, cell flare in the anterior chamber, lamellar macular 
hole formation, hard exudates deposits in the center of the macula, glaucoma, choroidal 
detachment, fibrinoid syndrome, and macular ischemia (Bhagat et al., 2009; Stolba et al., 2005; 
Yanyali et al., 2005). The incidence of intra and postoperative complications does not seem to 
differ among the different techniques, except when triamcinolone acetonide is used, leading to an 
IOP increase (Shiba et al., 2009). As for the long term effects of mechanical injury of ILM peeling, 
surgical skills are very important, but the ILM staining long-term effects are still unknown. 
Indocyanine green dye is potentially toxic to the retina (Gandorfer et al., 2001; Haritoglou et al., 
2001). Despite no toxicity reports with a 0.5 mg/ml dose in a minimum contact time, due to 
concerns, indocyanine green is no longer recommended to assist the ILM peeling. 
9 Other potential pharmacological therapeutics  
Ruboxistaurin is a specific protein kinase C beta inhibitor and therefore leads to VEGF-
induced leakage reduction. In an oral 32-mg/day dosage, it reduces the retinal vascular leakage, the 
progression to sight-threatening CSME and consequent rate of VA loss in eyes with severe DME. 
The clinical benefit may be more prominent in cases of severe macular edema (Aiello et al., 2007; 
Aiello et al., 2006; Davis et al., 2009; Strom et al., 2005). It is well tolerated, unlike multitarget 
kinase inhibitors, which are associated with more frequent adverse events (Campochiaro, 2004)  
Infliximab is a chimeric monoclonal antibody specific for human anti–tumor necrosis 
factor. The short-term outcomes of intravenous infliximab (5 mg/kg) in laser-refractory DME eyes, 
with severe VA impairment, are promising (Sfikakis et al., 2010). The safety is unknown; however, 
 
 
postmarketing surveillance data in thousands of patients treated with infliximab for other 
conditions show an excellent safety profile (Sfikakis, 2010). There are some evidences that the 
intravitreal approach may not provide the same performance and may actually lead to more serious 
ocular adverse effects (Wu et al., 2011). 
Sirolimus, also known as rapamycin, is a macrolide that, in complex with the 
immunophilin FK binding protein 12, inhibits the mammalian target of rapamycin, which is a key 
point of convergence for multiple intracellular regulatory pathways. This results, among others, in 
the inhibition of the expression and signaling of VEGF, inhibition of the activity of protein kinase 
C, and down regulation of the hypoxia-inducible factor 1α. The first randomized, dose-escalation 
study of sirolimus in DME patients suggests that both intraocular and subconjunctival injections 
(220 to 1760 µg) can provide therapeutic effects and are well-tolerated (Dugel et al., 2012). 
Due to potential surgical complications of vitrectomy, a few intravitreal drugs (such as 
autologous plasmin and tissue plasminogen activator) have been used to induce PVD without the 
need for vitrectomy. In diffuse DME, intravitreal autologous plasmin is able to reduce the macular 
thickening and improve VA, either as a primary treatment or in laser-refractory cases (Diaz-Llopis 
et al., 2009; Diaz-Llopis et al., 2008). The efficacy and toxicity is dose-dependent and a 0.4 IU 
dosage was demonstrated to be sufficient to separate the posterior vitreous cortex from the ILM 
without retinal toxicity (Azzolini et al., 2004; Wang et al., 2004). Intravitreal tissue plasminogen 
activator (25 µg) is able to induce PVD in patients with refractory DME, but without therapeutic 
benefit (Abrishami et al., 2011). However, the benefits from PVD induction are known to appear 
slowly and the study has a very short follow-up period, so it is expected that therapeutic responses 
may occur over time. 
Diclofenac, a nonsteroidal anti-inflammatory drug, inhibits the cyclooxygenase and 
lipooxygenase pathways. A recent report shows that short-term outcomes of intravenous diclofenac 
(500 µg) in diffuse DME eyes are promising, with comparable anatomical results to IVTA and no 
IOP increase. In 12 weeks, the functional improvement is lower compared with IVTA, but it is 
possible that with longer follow-up it may be at least identical (Elbendary and Shahin, 2011). 
Other drugs that also have shown interesting results are topical difluprednate eye drops 
(0.05%) (Nakano Goto et al., 2011; Nakano et al., 2010) and topical dexamethasone-cyclodextrin 
eye drops (Tanito et al., 2011). In addition, oral fenofibrate (200 mg/day) may be an adjuvant to 
photocoagulation, since it can reduce the need for laser treatment (Keech et al., 2007). 
10 Conclusions and future directions 
This review tried to gather as much evidence as possible concerning the treatment of DME 
in an attempt to analyze the results of recently used therapies and, if possible, predict the future 
trends in the following years. 
 The literature search method for this review was based on online Medline Pubmed 
database searches, the last one in January 2012. Randomized studies results, as the most reliable 
source of scientific evidence, were privileged. A meta-analysis is very difficult to perform, due to 
several limitations. Besides limitations inherent to short sample sizes and follow-up periods, there 
 
 
is also great variability when assessing results. The effectiveness of a specific treatment for DME is 
assessed mainly by anatomical (macular edema) and functional (vision acuity) parameters and 
there is a lack of uniformity among the studies while measuring these parameters: some measure 
the general macular thickness while others just the foveal thickness; for visual assessment some use 
the ETDRS charts (considered the most accurate and therefore the one required by FDA) and 
others the Snellen charts (considered faster and easier to use in clinical practice). Also, there are 
differences in the participants’ baseline characteristics between studies. For all these reasons, the 
comparison of results between studies for different therapies or even for the same therapy may be 
quite challenging. Nonetheless, despite obvious limitations, and assuming that future studies will 
confirm the trends exposed in this review, a prediction for the near future treatment of DME can be 
made. However with the increasing number of drugs under investigation and the growing interest 
in this subject, as confirmed by the exponential rise in the number of published articles in this area, 
treatment guidance may drastically change in the next few years.  
There is no cure for DME. Perhaps a cure will be possible once a cure for diabetes itself is 
accomplished. For now, the best way to deal with DME seems to be prevention, maintaining a tight 
blood sugar and pressure control in every diabetic patient, regardless of the presence of DME or 
any other diabetic-related retinopathy, as well as a regular monitoring to detect it as soon as 
possible.  
Once DME is establish, only limited management options can be offered to patients. To 
date, the best-studied treatments are laser photocoagulation, corticosteroids, VEFG inhibitors, and 
vitrectomy. The choice between them can be complicated, but, taking into account the 
effectiveness and safety, some orientations were suggested. The treatment must be dynamic, 
applied and changed according to the disease stage and response to therapies. Tight blood sugar 
and pressure control must be a priority regardless of the severity of the disease, since it influences 
the response to other treatments.  
In early CSME with no or little vision loss, laser photocoagulation should remain the first-
line treatment to delay the progression as much as possible, because it is a very effective treatment 
and no advantages would be obtain from other therapies. Due to long-term safety advantages and 
equal effectiveness, subthreshold micropulse diode laser or PASCAL® should be preferred, when 
available. Greater vision loss and more advanced stages of DME tend to be more refractory to laser 
treatment and, even when there is a response, visual improvement is rarely satisfactory. This is 
when other treatment modalities must be employed, perhaps as primary treatment in an attempt to 
recover some VA; afterwards, laser can be applied to help stabilize the improvements. Among 
these alternatives, VEFG inhibitors should be the first option, corticosteroids should be reserved for 
more difficult cases, and vitrectomy should be considered only if evidences of vitreoretinal 
interface abnormalities are found. The reason for preference of VEFG inhibitors is based on the 
observation that, in general, they seem to provide similar long-term responses to IVTA with much 
less adverse effects. Intravitreal delivery systems of corticosteroids show better safety profile than 
intravitreal injections, since they work in lower doses, but even so, VEFG inhibitors seem safer. If 
the initial promising results are confirmed by future studies, ruboxistaurin, infliximab, sirolimus 
and diclofenac are very likely to become VEFG inhibitors’ sidekicks and intravitreal PVD inducer 
 
 
drugs, such as autologous plasmin, may become the substitute for vitrectomy in macular traction 
cases. Combination of therapies, preferably in sequence, can be tried, because different therapies 
may, in some cases, potentiate the effect of each other, due to the differing modes of action.  
In the day-to-day practice, choice of therapies is based not only in effectiveness and safety 
but also in treatment costs. A tight monitoring of the adverse effects (mainly the IOP increase), an 
absence of history of ocular hypertension or glaucoma, and the fact that most diabetic patients will 
eventually need cataract surgery despite corticosteroids treatment, provides a risk–benefit ratio for 
intravitreal delivery systems of corticosteroids that justify their use over VEFG inhibitors. 
Ranibizumab was recently approved in some countries as treatment for DME. Other countries 
refuse ranibizumab considering it too expensive for the benefits it provides, preferring to wait for 
more bevacizumab studies, since it seems to provide similar clinical outcomes and is a cheaper 
alternative. After all, in the end, therapy decisions need to be discussed and made with patients, 
taking into account several patient-, treatment-, and cost-related factors.  
The network-like character of the pathophysiology and the different responses to the same 
treatment by different patients and in the same patient over time suggest that some pathways 
contribute more than others and they may differ between patients and over time. Therefore, the 
optimal therapy needs to be multi-targeted. A substance with multiple targets might not be the 
solution, since it might lead to more frequent adverse effects, as seen with corticosteroids. A 
combination of selective drugs with different molecular targets might be a better answer. Because 
these drugs do not affect the underlying cause of DME and the condition tends to be chronic, once 
they are cleared from the vitreous the macular edema tends to reappear. Thus, intravitreal delivery 
systems with a long half-life are better than repeated injections, since they provide a long, 
continuous and stable drug delivery. Consequently, these also allow the use of lower and safer 
doses. So, the logical ideal therapy would be a long-duration intravitreal delivery system that 
provides several selective inhibitory drugs simultaneously. Perhaps, in the future, technical 
improvements will allow the creation of such a product, and it may, hypothetically, revolutionize 
DME treatment. On the other hand, several studies have shown that susceptibility to the 
development of DR may have a heritable component, independent of glycemic control and duration 
of diabetes; sequence variation in the VEGF-A gene is one example (Abhary et al., 2009). 
Therefore, the identification of specific genetic risk factors for diabetic retinopathy might improve 
not only the screening algorithms but also the treatment approach.  
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